A WAO - ARIA - GA2LEN consensus document on molecular-based allergy diagnostics

Giorgio Walter Canonica; Ignacio J Ansotegui; Ruby Pawankar; Peter Schmid-Grendelmeier; Marianne van Hage; Carlos E Baena-Cagnani; Giovanni Melioli; Carlos Nunes; Giovanni Passalacqua; Lanny Rosenwasser; Hugh Sampson; Joaquin Sastre; Jean Bousquet; Torsten Zuberbier; Katrina Allen; Riccardo Asero; Barbara Bohle; Linda Cox; Frederic de Blay; Motohiro Ebisawa; René Maximiliano-Gómez; Sandra González-Diaz; Tari Haahtela; Stephen Holgate; Thilo Jakob; Mark Larché; Paolo Maria Matricardi; John Oppenheimer; Lars K. Poulsen; Harald E Renz; Nelson Rosário; Marc Rothenberg; Mario Sanchez-Borges; Enrico Scala; Rudolf Valenta

doi:10.1186/1939-4551-6-17

A WAO - ARIA - GA2LEN consensus document on molecular-based allergy diagnostics

Giorgio Walter Canonica, Ignacio J Ansotegui, Ruby Pawankar, Peter Schmid-Grendelmeier, Marianne van Hage, Carlos E Baena-Cagnani, Giovanni Melioli, Carlos Nunes, Giovanni Passalacqua, Lanny Rosenwasser, Hugh Sampson, Joaquin Sastre, Jean Bousquet, Torsten Zuberbier, Katrina Allen, Riccardo Asero, Barbara Bohle, Linda Cox, Frederic de Blay, Motohiro EbisawaRené Maximiliano-Gómez, Sandra González-Diaz, Tari Haahtela, Stephen Holgate, Thilo Jakob, Mark Larché, Paolo Maria Matricardi, John Oppenheimer, Lars K. Poulsen, Harald E Renz, Nelson Rosário, Marc Rothenberg, Mario Sanchez-Borges, Enrico Scala, Rudolf Valenta

Department of Clinical Medicine

284 Citations (Scopus)

Abstract

Molecular-based allergy (MA) diagnostics is an approach used to map the allergen sensitization of a patient at a molecular level, using purified natural or recombinant allergenic molecules (allergen components) instead of allergen extracts. Since its introduction, MA diagnostics has increasingly entered routine care, with currently more than 130 allergenic molecules commercially available for in vitro specific IgE (sIgE) testing.MA diagnostics allows for an increased accuracy in allergy diagnosis and prognosis and plays an important role in three key aspects of allergy diagnosis: (1) resolving genuine versus cross-reactive sensitization in poly-sensitized patients, thereby improving the understanding of triggering allergens; (2) assessing, in selected cases, the risk of severe, systemic versus mild, local reactions in food allergy, thereby reducing unnecessary anxiety for the patient and the need for food challenge testing; and (3) identifying patients and triggering allergens for specific immunotherapy (SIT).Singleplex and multiplex measurement platforms are available for MA diagnostics. The Immuno-Solid phase Allergen Chip (ISAC) is the most comprehensive platform currently available, which involves a biochip technology to measure sIgE antibodies against more than one hundred allergenic molecules in a single assay. As the field of MA diagnostics advances, future work needs to focus on large-scale, population-based studies involving practical applications, elucidation and expansion of additional allergenic molecules, and support for appropriate test interpretation. With the rapidly expanding evidence-base for MA diagnosis, there is a need for allergists to keep abreast of the latest information. The aim of this consensus document is to provide a practical guide for the indications, determination, and interpretation of MA diagnostics for clinicians trained in allergology.

Original language	English
Journal	The World Allergy Organization Journal
Volume	6
Issue number	1
Pages (from-to)	17
ISSN	1939-4551
DOIs	https://doi.org/10.1186/1939-4551-6-17
Publication status	Published - 3 Oct 2013

Access to Document

10.1186/1939-4551-6-17

Cite this

Canonica, G. W., Ansotegui, I. J., Pawankar, R., Schmid-Grendelmeier, P., van Hage, M., Baena-Cagnani, C. E., Melioli, G., Nunes, C., Passalacqua, G., Rosenwasser, L., Sampson, H., Sastre, J., Bousquet, J., Zuberbier, T., Allen, K., Asero, R., Bohle, B., Cox, L., de Blay, F., ... Valenta, R. (2013). A WAO - ARIA - GA2LEN consensus document on molecular-based allergy diagnostics. The World Allergy Organization Journal, 6(1), 17. https://doi.org/10.1186/1939-4551-6-17

Canonica, GW, Ansotegui, IJ, Pawankar, R, Schmid-Grendelmeier, P, van Hage, M, Baena-Cagnani, CE, Melioli, G, Nunes, C, Passalacqua, G, Rosenwasser, L, Sampson, H, Sastre, J, Bousquet, J, Zuberbier, T, Allen, K, Asero, R, Bohle, B, Cox, L, de Blay, F, Ebisawa, M, Maximiliano-Gómez, R, González-Diaz, S, Haahtela, T, Holgate, S, Jakob, T, Larché, M, Matricardi, PM, Oppenheimer, J, Poulsen, LK, Renz, HE, Rosário, N, Rothenberg, M, Sanchez-Borges, M, Scala, E & Valenta, R 2013, 'A WAO - ARIA - GA2LEN consensus document on molecular-based allergy diagnostics', The World Allergy Organization Journal, vol. 6, no. 1, pp. 17. https://doi.org/10.1186/1939-4551-6-17

@article{ce15da3bf7b14160bdfda94d70813057,

title = "A WAO - ARIA - GA2LEN consensus document on molecular-based allergy diagnostics",

abstract = "Molecular-based allergy (MA) diagnostics is an approach used to map the allergen sensitization of a patient at a molecular level, using purified natural or recombinant allergenic molecules (allergen components) instead of allergen extracts. Since its introduction, MA diagnostics has increasingly entered routine care, with currently more than 130 allergenic molecules commercially available for in vitro specific IgE (sIgE) testing.MA diagnostics allows for an increased accuracy in allergy diagnosis and prognosis and plays an important role in three key aspects of allergy diagnosis: (1) resolving genuine versus cross-reactive sensitization in poly-sensitized patients, thereby improving the understanding of triggering allergens; (2) assessing, in selected cases, the risk of severe, systemic versus mild, local reactions in food allergy, thereby reducing unnecessary anxiety for the patient and the need for food challenge testing; and (3) identifying patients and triggering allergens for specific immunotherapy (SIT).Singleplex and multiplex measurement platforms are available for MA diagnostics. The Immuno-Solid phase Allergen Chip (ISAC) is the most comprehensive platform currently available, which involves a biochip technology to measure sIgE antibodies against more than one hundred allergenic molecules in a single assay. As the field of MA diagnostics advances, future work needs to focus on large-scale, population-based studies involving practical applications, elucidation and expansion of additional allergenic molecules, and support for appropriate test interpretation. With the rapidly expanding evidence-base for MA diagnosis, there is a need for allergists to keep abreast of the latest information. The aim of this consensus document is to provide a practical guide for the indications, determination, and interpretation of MA diagnostics for clinicians trained in allergology.",

author = "Canonica, {Giorgio Walter} and Ansotegui, {Ignacio J} and Ruby Pawankar and Peter Schmid-Grendelmeier and {van Hage}, Marianne and Baena-Cagnani, {Carlos E} and Giovanni Melioli and Carlos Nunes and Giovanni Passalacqua and Lanny Rosenwasser and Hugh Sampson and Joaquin Sastre and Jean Bousquet and Torsten Zuberbier and Katrina Allen and Riccardo Asero and Barbara Bohle and Linda Cox and {de Blay}, Frederic and Motohiro Ebisawa and Ren{\'e} Maximiliano-G{\'o}mez and Sandra Gonz{\'a}lez-Diaz and Tari Haahtela and Stephen Holgate and Thilo Jakob and Mark Larch{\'e} and Matricardi, {Paolo Maria} and John Oppenheimer and Poulsen, {Lars K.} and Renz, {Harald E} and Nelson Ros{\'a}rio and Marc Rothenberg and Mario Sanchez-Borges and Enrico Scala and Rudolf Valenta",

year = "2013",

month = oct,

day = "3",

doi = "10.1186/1939-4551-6-17",

language = "English",

volume = "6",

pages = "17",

journal = "The World Allergy Organization Journal",

issn = "1939-4551",

publisher = "BioMed Central Ltd.",

number = "1",

}

TY - JOUR

T1 - A WAO - ARIA - GA2LEN consensus document on molecular-based allergy diagnostics

AU - Canonica, Giorgio Walter

AU - Ansotegui, Ignacio J

AU - Pawankar, Ruby

AU - Schmid-Grendelmeier, Peter

AU - van Hage, Marianne

AU - Baena-Cagnani, Carlos E

AU - Melioli, Giovanni

AU - Nunes, Carlos

AU - Passalacqua, Giovanni

AU - Rosenwasser, Lanny

AU - Sampson, Hugh

AU - Sastre, Joaquin

AU - Bousquet, Jean

AU - Zuberbier, Torsten

AU - Allen, Katrina

AU - Asero, Riccardo

AU - Bohle, Barbara

AU - Cox, Linda

AU - de Blay, Frederic

AU - Ebisawa, Motohiro

AU - Maximiliano-Gómez, René

AU - González-Diaz, Sandra

AU - Haahtela, Tari

AU - Holgate, Stephen

AU - Jakob, Thilo

AU - Larché, Mark

AU - Matricardi, Paolo Maria

AU - Oppenheimer, John

AU - Poulsen, Lars K.

AU - Renz, Harald E

AU - Rosário, Nelson

AU - Rothenberg, Marc

AU - Sanchez-Borges, Mario

AU - Scala, Enrico

AU - Valenta, Rudolf

PY - 2013/10/3

Y1 - 2013/10/3

N2 - Molecular-based allergy (MA) diagnostics is an approach used to map the allergen sensitization of a patient at a molecular level, using purified natural or recombinant allergenic molecules (allergen components) instead of allergen extracts. Since its introduction, MA diagnostics has increasingly entered routine care, with currently more than 130 allergenic molecules commercially available for in vitro specific IgE (sIgE) testing.MA diagnostics allows for an increased accuracy in allergy diagnosis and prognosis and plays an important role in three key aspects of allergy diagnosis: (1) resolving genuine versus cross-reactive sensitization in poly-sensitized patients, thereby improving the understanding of triggering allergens; (2) assessing, in selected cases, the risk of severe, systemic versus mild, local reactions in food allergy, thereby reducing unnecessary anxiety for the patient and the need for food challenge testing; and (3) identifying patients and triggering allergens for specific immunotherapy (SIT).Singleplex and multiplex measurement platforms are available for MA diagnostics. The Immuno-Solid phase Allergen Chip (ISAC) is the most comprehensive platform currently available, which involves a biochip technology to measure sIgE antibodies against more than one hundred allergenic molecules in a single assay. As the field of MA diagnostics advances, future work needs to focus on large-scale, population-based studies involving practical applications, elucidation and expansion of additional allergenic molecules, and support for appropriate test interpretation. With the rapidly expanding evidence-base for MA diagnosis, there is a need for allergists to keep abreast of the latest information. The aim of this consensus document is to provide a practical guide for the indications, determination, and interpretation of MA diagnostics for clinicians trained in allergology.

AB - Molecular-based allergy (MA) diagnostics is an approach used to map the allergen sensitization of a patient at a molecular level, using purified natural or recombinant allergenic molecules (allergen components) instead of allergen extracts. Since its introduction, MA diagnostics has increasingly entered routine care, with currently more than 130 allergenic molecules commercially available for in vitro specific IgE (sIgE) testing.MA diagnostics allows for an increased accuracy in allergy diagnosis and prognosis and plays an important role in three key aspects of allergy diagnosis: (1) resolving genuine versus cross-reactive sensitization in poly-sensitized patients, thereby improving the understanding of triggering allergens; (2) assessing, in selected cases, the risk of severe, systemic versus mild, local reactions in food allergy, thereby reducing unnecessary anxiety for the patient and the need for food challenge testing; and (3) identifying patients and triggering allergens for specific immunotherapy (SIT).Singleplex and multiplex measurement platforms are available for MA diagnostics. The Immuno-Solid phase Allergen Chip (ISAC) is the most comprehensive platform currently available, which involves a biochip technology to measure sIgE antibodies against more than one hundred allergenic molecules in a single assay. As the field of MA diagnostics advances, future work needs to focus on large-scale, population-based studies involving practical applications, elucidation and expansion of additional allergenic molecules, and support for appropriate test interpretation. With the rapidly expanding evidence-base for MA diagnosis, there is a need for allergists to keep abreast of the latest information. The aim of this consensus document is to provide a practical guide for the indications, determination, and interpretation of MA diagnostics for clinicians trained in allergology.

U2 - 10.1186/1939-4551-6-17

DO - 10.1186/1939-4551-6-17

M3 - Journal article

C2 - 24090398

SN - 1939-4551

VL - 6

SP - 17

JO - The World Allergy Organization Journal

JF - The World Allergy Organization Journal

IS - 1

ER -

A WAO - ARIA - GA2LEN consensus document on molecular-based allergy diagnostics

Abstract

Access to Document

Fingerprint

Cite this